Amgen Drops Alexion Blood Drug IPRs, Gets 2025 License
Amgen has agreed to drop three challenges to patents covering Alexion's blockbuster blood disorder treatment Soliris in exchange for a license that would let it make and sell a biosimilar version...To view the full article, register now.
Already a subscriber? Click here to view full article